Editas Medicine Inc (EDIT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access EDIT quarterly Cash Flow →
Cash flow patterns shown here provide context for understanding Editas Medicine Inc's ability to sustain operations and capital deployment.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-160.06
Depreciation & amortization5.28
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets to be Disposed of3.76
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment2.19
Share-based Compensation10.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Fair Value Adjustment Of Rights-
Fair Value Adjustment Of Anti Dilution Protection Liability-
Noncash Investment In Equity Securities-
Increase Decrease In Contract With Customer Liability-15.92
Increase Decrease In Right Of Use Assets11.58
Investment Income Net Amortization Of Discount And Premium-0.90
Interest Related To Sale Of Future Revenues6.17
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable1.09
Increase (Decrease) in Accounts Payable-2.89
Increase (Decrease) in Accrued Liabilities-13.18
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.06
Other Working Capital1.23
Other Noncash Income (Expense)-0.45
Other net0.00
Payments for (Proceeds from) Other Operating Activities-14.21
Discontinued operations0.00
Net Cash flow from Operating Activities-165.24
Investing Activities
Capital Expenditures-0.61
Sale of Capital Items0.27
Proceeds from Sale and Maturity of Marketable Securities139.01
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Proceeds From Sale Of Equity Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities138.67
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-2.87
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock43.34
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-135.42
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents135.42
Proceeds From Issuance Of Debt Net Of Payment Of Debt Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities40.47
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-165.58
Total Cash Flow13.90
4 historic quarters locked

Sign in to unlock the full Editas Medicine Inc cash flow history.

About Editas Medicine Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001650664-26-000017

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License